H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the shares after the company recently announced a global license and collaboration agreement with Sarepta Therapeutics (SRPT) that is expected to support further development of the company’s wholly-owned pipeline and support Arrowhead through the potential commercial launch of its first RNA interference therapeutic anticipated in 2026. The firm, which believes the Sarepta deal is a “clear positive,” calls it “the primary driver of our price target increase” as it should provide sufficient capital to fund Arrowhead’s “underappreciated” internal pipeline.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Arrowhead requests regulatory clearance to initiate ARO-ALK7 trial
- Sarepta price target lowered to $75 from $80 at H.C. Wainwright
- Arrowhead price target lowered to $24 from $27 at Bernstein
- Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance
- Dell and HP forecasts spark selloffs: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
